Publication | Closed Access
Rituximab in refractory myasthenia gravis: Extended prospective study results
67
Citations
11
References
2018
Year
Sustained clinical improvement was associated with rituximab after 1 cycle, with prolonged time to relapse and reduction in steroid dosage. Muscle Nerve 58: 453-456, 2018.
| Year | Citations | |
|---|---|---|
Page 1
Page 1